Paul L. M. van Giersbergen

First‐in‐man safety and pharmacokinetics of synthetic ozonide <scp>OZ439</scp> demonstrates an improved exposure profile relative to other peroxide antimalarials

Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff et al. · British Journal of Clinical Pharmacology · 2012 · 115 citations · Full text

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

Patricia N. Sidharta, Paul L. M. van Giersbergen, Atef Halabi et al. · European Journal of Clinical Pharmacology · 2011 · 107 citations · Full text

A toxin from the green mamba <i>Dendroaspis angusticeps</i>: Amino acid sequence and selectivity for muscarinic m4 receptors

Mikael Jolkkonen, Paul L. M. van Giersbergen, Ulf Hellman et al. · FEBS Letters · 1994 · 93 citations

Muscarinic M4 Receptors, Amino Acids, Biochemistry +13

Single‐ and multiple‐dose pharmacokinetics of bosentan and its interaction with ketoconazole

Paul L. M. van Giersbergen, Atef Halabi, Jasper Dingemanse · British Journal of Clinical Pharmacology · 2002 · 86 citations · Full text

Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT₃ receptors

Robert C. Miller, Martin Galvan, Maurice W. Gittos et al. · Drug Development Research · 1993 · 81 citations

Sympathetic Nerve Terminals, Pharmacotherapy, Experimental Pharmacology +20